Addressing large and
growing unmet needs

89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The company’s lead product candidate, BIO89-100, is a specifically engineered glycoPEGylated analog of FGF21. BIO89-100 is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). 89bio is headquartered in San Francisco with operations in Herzliya, Israel.

Leadership

Rohan Palekar
CEO
Ram Waisbourd
Chief Operating Officer and
Chief Business Officer
Dr. Hank Mansbach
Chief Medical Officer
Quoc Le-Nguyen
Chief Technical Operations Officer and
Head of Quality
Ryan Martins
Chief Financial Officer
Melissa Abel
VP, Commercial Strategy & Communication
Michael Baldwin
VP, Quality Assurance
Dr. Will Charlton
VP, Clinical Development
Shiva Natarajan
VP, Finance & Principal Accounting Officer
Moti Rosenstock
VP, Preclinical Development
Paul Shin
VP, R&D Operations

Board of Directors

Dr. Steven Altschuler (Chairman)
Managing Director, Ziff Capital Partners
Anat Naschitz
Managing Director, OrbiMed
Dr. Greg Grunberg
Managing Director, Longitude Capital
Derek DiRocco, PhD
Principal, RA Capital Management
Dr. Michael Hayden
CM, BC, MBChB, PhD, FRCP(C), FRSC
Lota Zoth
CPA
Rohan Palekar
CEO